AU2005263331B8 - Anti-Rhesus D recombinant polyclonal antibody and methods of manufacture - Google Patents

Anti-Rhesus D recombinant polyclonal antibody and methods of manufacture Download PDF

Info

Publication number
AU2005263331B8
AU2005263331B8 AU2005263331A AU2005263331A AU2005263331B8 AU 2005263331 B8 AU2005263331 B8 AU 2005263331B8 AU 2005263331 A AU2005263331 A AU 2005263331A AU 2005263331 A AU2005263331 A AU 2005263331A AU 2005263331 B8 AU2005263331 B8 AU 2005263331B8
Authority
AU
Australia
Prior art keywords
rhd
cells
antibody
individual
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005263331A
Other languages
English (en)
Other versions
AU2005263331A1 (en
AU2005263331A8 (en
AU2005263331B2 (en
Inventor
Soren Bregenholt Frederiksen
John Haurum
Soren Kofoed Rasmussen
Anne Bondgaard Tolstrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of AU2005263331A1 publication Critical patent/AU2005263331A1/en
Application granted granted Critical
Publication of AU2005263331B2 publication Critical patent/AU2005263331B2/en
Publication of AU2005263331B8 publication Critical patent/AU2005263331B8/en
Publication of AU2005263331A8 publication Critical patent/AU2005263331A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2005263331A 2004-07-20 2005-07-18 Anti-Rhesus D recombinant polyclonal antibody and methods of manufacture Ceased AU2005263331B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200401133 2004-07-20
DKPA200401133 2004-07-20
DKPA200401992 2004-12-22
DKPA200401992 2004-12-22
PCT/DK2005/000501 WO2006007850A1 (en) 2004-07-20 2005-07-18 Anti-rhesus d recombinant polyclonal antibody and methods of manufacture

Publications (4)

Publication Number Publication Date
AU2005263331A1 AU2005263331A1 (en) 2006-01-26
AU2005263331B2 AU2005263331B2 (en) 2011-05-26
AU2005263331B8 true AU2005263331B8 (en) 2011-06-16
AU2005263331A8 AU2005263331A8 (en) 2011-06-16

Family

ID=35159789

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005263331A Ceased AU2005263331B8 (en) 2004-07-20 2005-07-18 Anti-Rhesus D recombinant polyclonal antibody and methods of manufacture

Country Status (13)

Country Link
US (2) US8198415B2 (https=)
EP (2) EP1771483A1 (https=)
JP (1) JP4926054B2 (https=)
KR (1) KR20070038556A (https=)
AU (1) AU2005263331B8 (https=)
BR (1) BRPI0513706A (https=)
CA (1) CA2574062A1 (https=)
EA (1) EA014182B1 (https=)
IL (1) IL179658A (https=)
MX (1) MX2007000644A (https=)
NO (1) NO20070927L (https=)
NZ (1) NZ552265A (https=)
WO (1) WO2006007850A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
ES2273202T3 (es) * 2003-01-07 2007-05-01 Symphogen A/S Procedimiento para producir proteinas policlonales recombinantes.
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
EP2314619A1 (en) 2005-12-05 2011-04-27 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
PT2121920E (pt) 2007-03-01 2011-10-03 Symphogen As Método de clonagem de anticorpos cognatos
CN101675075B (zh) * 2007-03-01 2014-06-18 西福根有限公司 重组抗表皮生长因子受体抗体组合物
WO2008106980A2 (en) 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
HRP20100640T1 (hr) 2007-05-25 2010-12-31 Symphogen A/S Postupak proizvodnje rekombinantnog poliklonskog proteina
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
CA2695309A1 (en) * 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
US20090093004A1 (en) * 2007-10-04 2009-04-09 Symphogen A/S Potency assay
CA2702322A1 (en) * 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
RU2010147652A (ru) * 2008-04-23 2012-05-27 Симфоген А/С (Dk) Способы производства поликлонального белка
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20110047258A (ko) * 2008-08-26 2011-05-06 심포젠 에이/에스 저혈소판증의 치료 방법
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
RU2011111725A (ru) * 2008-08-29 2012-10-10 Симфоген А/С (Dk) Способ клонирования антител птиц
US20110224094A1 (en) * 2008-10-06 2011-09-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
RU2012118620A (ru) 2009-10-09 2013-11-20 Симфоген А/С Множественное количественное определение в смеси индивидуальных рекомбинантных белков посредством сигнатурных пептидов и масс-спектрометрии
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
LT2864346T (lt) * 2012-06-21 2019-01-25 Synthon Biopharmaceuticals B.V. Antikūnų gryninimo metodas
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
SG11201601763SA (en) 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017184973A1 (en) 2016-04-22 2017-10-26 University Of Tennessee Research Foundation Identifying amyloidogenic proteins & amyloidogenic risk
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
SMT202300418T1 (it) 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
CN112513074A (zh) * 2018-06-22 2021-03-16 健玛保 生产两种或更多种不同抗体的受控混合物的方法
EP3870604B1 (en) 2018-10-26 2022-11-23 F. Hoffmann-La Roche AG Multispecific antibody screening method using recombinase mediated cassette exchange
CN113661173B (zh) 2019-03-29 2024-10-01 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生表达FcRn的细胞的方法
US12479908B2 (en) 2019-03-29 2025-11-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Antibodies against programmed cell death protein 1 (PD1) and uses thereof
CN113993887A (zh) 2019-06-19 2022-01-28 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生多价双特异性抗体表达细胞的方法
BR112021025462A2 (pt) 2019-06-19 2022-02-01 Hoffmann La Roche Métodos para produzir um anticorpo bivalente biespecífico e uma célula de mamífero recombinante, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante e composição
WO2020254352A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
KR20220010024A (ko) 2019-06-19 2022-01-25 에프. 호프만-라 로슈 아게 Cre mrna를 이용한 표적화된 통합에 의한 단백질 발현 세포의 산출을 위한 방법
JP7572977B2 (ja) 2019-06-19 2024-10-24 エフ． ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットの標的化組込みによって多価の多重特異性抗体発現細胞を作製するための方法
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
TW202237642A (zh) * 2021-01-08 2022-10-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
RU2770654C1 (ru) * 2021-06-17 2022-04-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) Способ профилактики тяжелой формы гемолитической болезни новорожденных при резус-иммунизации у беременных с соматической патологией и потерями плода в анамнезе
WO2025039046A1 (en) * 2023-08-23 2025-02-27 The Walter And Eliza Hall Institute Of Medical Research Anti-rhesus d human monoclonal antibodies
CN119176879B (zh) * 2024-09-05 2025-08-05 西安市中心血站（陕西省血液中心） 一种中和抗d抗体的抗独特型抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020401A1 (en) * 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
WO1997049809A1 (en) * 1996-06-24 1997-12-31 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use
WO2002044361A2 (en) * 2000-11-28 2002-06-06 Applied Molecular Evolution, Inc. Eukaryotic expression libraries based on double lox recombination and methods of use
AU2004203727A1 (en) * 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002413A1 (en) 1983-11-28 1985-06-06 The Board Of Trustees Of The Leland Stanford Jr. U HUMAN MONOCLONAL ANTIBODY AGAINST Rh(D) ANTIGEN AND ITS USES
US5126130A (en) * 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
GB8722019D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722018D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722020D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
GB8906129D0 (en) 1989-03-17 1989-05-04 Central Blood Lab Authority Pharmaceutical preparations
GB8919761D0 (en) 1989-09-01 1989-10-18 Central Blood Lab Authority Chemical compounds
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
CA2116246A1 (en) 1992-06-26 1994-01-06 Roland Beliard Human monoclonal anti-rhesus (d) antibodies and cell lines producing same
KR100306635B1 (ko) 1992-10-21 2001-11-30 스테판밀테니 분비생성물에의한직접적인세포선별
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
FR2724182B1 (fr) * 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US5876925A (en) * 1996-10-11 1999-03-02 The Trustees Of The University Of Pennsylvania Magnetically activated cell sorting for production of proteins
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6187994B1 (en) 1997-11-18 2001-02-13 Pioneer Hi-Bred International, Inc. Compositions and methods for genetic modification of plants
CN100365127C (zh) 1998-07-21 2008-01-30 密理博公司 具有遍在染色质开放表达元件(ucoe)的聚核苷酸
US20020155114A1 (en) * 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
JP4808880B2 (ja) 1999-07-23 2011-11-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア バクテリオファージｐｈｉｃ３１組み換え系による真核細胞におけるｄｎａ組み換え
EP1106625A1 (en) 1999-11-17 2001-06-13 ZLB Bioplasma AG Rhesus D specific peptide sequences
EP1358202A2 (en) 2000-02-08 2003-11-05 The Regents Of The University Of Michigan Protein separation and display
WO2001059460A2 (en) 2000-02-08 2001-08-16 The Regents Of The University Of Michigan Mapping of differential display of proteins
WO2001058926A2 (en) 2000-02-08 2001-08-16 The Regents Of The University Of Michigan Protein mapping
JP2003534290A (ja) 2000-05-26 2003-11-18 シムフォゲン アクティーゼルスカブ アレルギー治療用の組換えまたは精製ポリクロナール抗体
CA2416701A1 (en) 2000-07-21 2002-01-31 The United States Of America, As Represented By The Secretary Of Agricul Ture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
WO2002052259A1 (en) 2000-12-26 2002-07-04 The Institute For Systems Biology Rapid and quantitative proteome analysis and related methods
WO2003102539A2 (en) 2002-05-31 2003-12-11 The Regents Of The University Of Michigan Automated protein analysis system comprising capillary electrophoresis-tandem mass spectrometry
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
WO2004035169A2 (en) 2002-10-15 2004-04-29 The Regents Of The University Of Michigan Multidimensional protein separation system
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020401A1 (en) * 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
US5789208A (en) * 1994-01-31 1998-08-04 The Trustees Of Boston University Polyclonal antibody libraries
WO1997049809A1 (en) * 1996-06-24 1997-12-31 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use
WO2002044361A2 (en) * 2000-11-28 2002-06-06 Applied Molecular Evolution, Inc. Eukaryotic expression libraries based on double lox recombination and methods of use
AU2004203727A1 (en) * 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BREGENHOLT S. & HAURUM J.: EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, March 2004, vol. 4, no. 3, pages 387-396 *
SELINGER M.: BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, June 1991, vol. 98, no. 6, pages 509 - 512 *
SHARON J. ET AL.: METHODS IN MOLECULAR BIOLOGY, 2002, vol. 178, pages 101-112 *
STUCKI. M., ET AL.: 'Characterisation of a chromatographically produced anti-D immunoglobulin product', JOURNAL OF CHROMATOGRAPHY B : BIOMEDICAL APPLICATIONS, 24 October 1997 (1997-10-24), vol. 700, no. 1-2, pages 241 - 248 *

Also Published As

Publication number Publication date
EA014182B1 (ru) 2010-10-29
EP1967529A1 (en) 2008-09-10
US20120322690A1 (en) 2012-12-20
IL179658A0 (en) 2007-05-15
KR20070038556A (ko) 2007-04-10
US20090017017A1 (en) 2009-01-15
NO20070927L (no) 2007-04-19
BRPI0513706A (pt) 2008-05-13
AU2005263331A1 (en) 2006-01-26
EP1771483A1 (en) 2007-04-11
JP4926054B2 (ja) 2012-05-09
CA2574062A1 (en) 2006-01-26
EA200700249A1 (ru) 2007-06-29
JP2008509658A (ja) 2008-04-03
NZ552265A (en) 2009-04-30
US8198415B2 (en) 2012-06-12
AU2005263331A8 (en) 2011-06-16
MX2007000644A (es) 2007-03-28
AU2005263331B2 (en) 2011-05-26
WO2006007850A1 (en) 2006-01-26
IL179658A (en) 2011-08-31

Similar Documents

Publication Publication Date Title
AU2005263331B8 (en) Anti-Rhesus D recombinant polyclonal antibody and methods of manufacture
AU2004203727B2 (en) Method for manufacturing recombinant polyclonal proteins
CA2683800C (en) Method for manufacturing a recombinant polyclonal protein
US9012371B2 (en) Mixtures of binding proteins
US20060275766A1 (en) Method for manufacturing recombinant polyclonal proteins
CN101023101A (zh) 抗－恒河猴d重组多克隆抗体和生产方法
CN100383244C (zh) 用于生产重组多克隆蛋白质的方法
AU2008201796A1 (en) Method for manufacturing recombinant polyclonal proteins
HK1078896B (en) Method for manufacturing recombinant polyclonal proteins
HK1134519B (en) Method for manufacturing a recombinant polyclonal protein

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 20, NO 49, PAGE(S) 4958 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SYMPHOGEN A/G, APPLICATION NO. 2005263331, UNDER INID (71) CORRECT THE APPLICANT NAME TO SYMPHOGEN A/S

Free format text: IN VOL 25, NO 20, PAGE(S) 2585 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME SYMPHOGEN A/G, APPLICATION NO. 2005263331, UNDER INID (71) CORRECT THE APPLICANT NAME TO SYMPHOGEN A/S

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired